Thrombocytopenia and prospective endovascular intervention in a patient with coronary artery disease
https://doi.org/10.21518/2079-701X-2018-21-16-21
Abstract
Thrombocytopenia in blood count may be a reflex of haemostatic problems of different origin – from autoimmune disease to iatrogenic nature. Sometimes, thrombocytopenia may be revealed in patient with coronary heart disease before PCI procedure as well as some hours or days later. Dual antithrombotic therapy and thrombocytopenia have the same main side effect – bleeding. Etiology of disease and details of medical decision before percutаneous coronary intervention (PCI) in CHD patients are discussed.
About the Authors
A. B. SumarokovRussian Federation
Sumarokov Alexander Borisovich – Cand. of Sci. (Med), Senior Researcher of the Department of Clinical Problems in Atherothrombosis
15А 3rd Cherepkovskaya ul., Moscow, 121552
L. I. Buryachkovskaya
Russian Federation
Buryachkovskaya Lyudmila Ivanovna – Dr. of Sci. (Bio), Head of the Thrombosis Mechanisms Group, Institute of Experimental Cardiology
15А 3rd Cherepkovskaya ul., Moscow, 121552
N. V. Lomakin
Russian Federation
Lomakin Nikita Valeryevich – Cand. of Sci. (Med), Chief Cardiologist
15 Marshal Timoshenko, Moscow, 121359
References
1. Yadav M., Genereux P., Giustino G., Madhavan M.V., Brener S.J., Mintz G., Caixeta A., Xu K., Mehran R., Stone G.W. Effect of baseline thrombocytopenia on ischemic outcomes in patients with аcute coronary syndromes who undergo percutaneous coronary intervention. Canadian J Cardiology. 2016; 32: 226-233.
2. Vora A.N., Chenier M., Schulte P.J., Goodman S., Peterson E.D., Pieper K., Joulicoeur M.E., Mahaffey K.W., White H., Wang T.Y. Long-tern outcomes associated with hospital acquired thrombocytopenia among patients with nonST-segment elevation acute coronary syndrome. Am Heart J. 2014; 168(2): 189-196.
3. Wang T., Ou F-S., Roe M., Harrington R., Ohman E., Gibler W., Peterson E. Incidence and prognostic significance of thrombocytopenia developed during Acute Coronary Syndrome in contemporary clinical practice. Circulation. 2009; 119(18): 2454-2462.
4. Hakim D., Dangas G., Caixeta A., Nikolsky E., Lancky A., Moses J., Claesen B., Sanidas E., White H., Ohman E., Manoukian S., Fahy M., Mehrah R., Stone G. Impact of baseline thrombocytopenia on early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONZ-AMI) trial. Am Heart J. 2011; 161(2): 391-396.
5. Raphael C., Spoon D., Bell M., Psaltis P., Kidd S., Loh S., Lennon R., Singh M., Rihal C., Gulati R. Effect of preprocedural thrombocytopenia on prognosis after percutaneous coronary intervention. Mayo Clinic Proceedings. 2016; 91(8): 1035-1044.
6. Campo G., Marchesini J., Filetti L, Tebaldi M., Ferrari R. Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary interventions. J Thrombosis Haemost. 2012; 10(1): 153-156.
7. Balduini C., Noris P. Platelet count and aging. Haematologica. 2014; 99(6): 953-955.
8. McCarthy С., Steg G., Bhatt D. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J. 2017; 38(Issue 47): 3488–3492.
9. Melikyan A.L,, Pustovaja E.I., Tsvetaev N.V., Abdulkadirov K.M., Lisucov I.A., Gritsaev S.V., Golenkov A.K., Davidkin I.L., Ivanova V.L., Shatochin J.V., Savchenko V.G., National clinical guidelines for the diagnosis and treatment of primary immune thrombocytopenia (idiopathic thrombocytopenic purpura) in adults. Gematologija i transfusiologija, 2015; 60(1): 44-56 (In Russ).
10. Jacob S., Dunn B., Qureshi Z., Bandarenko N., Kwan H., Randey D., MacKoy J., Barnato S., Winters J., Cursio J., Weiss I., Raife T., Carey P., Sarode R., Kiss J., Danielson Ortel T., Clark W., Rock G., Matsumoto M., Fujimura Y., Zheng X., Chen H., Chen F., Armstrong J., Raisch D., Benneth C. Ticlipidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: A 20Year Review from the Southern Network on Adverce Reactions (SONAR). Semin Thromb Hemost. 2012; 38(8): 845-853.
11. Siao W-Z., Chuang W-Y., Su C-H., Huang S-F., Tu W-K., Chan K-C. A rare case of ticagrelor isolated thrombocytopenia. Acta Cardiol Sin. 2017; 33: 556-558.
12. Melikyan A.L., Pustovaja E.I., Ugorova E.K., Kalinina M.V., Kolothsheynova T.I., Subortceva I.N., Gilazitdinova E.A., Dvirnyk V.N. Differential diagnosis of thrombocytopenia. Oncogematologia, 2017; 12(1): 78-8 (In Russ).
13. Zotova I.I., Gritsaev C.V., Bessmeltsev S.S. Primary immune thrombocytopenia. The current understanding of the pathogenesis and treatment, in Russian. The bulletin of hematology. 2017; 13(4): 48-63 (In Russ).
14. Narasimha D., Jutzu K., Hillard A. Percutaneous Coronary Intervention in Patients with Heparin Induced Thrombocytopenia: Case Report and Review of Literature. Cardiovasc Pharm Open Access journal. 2016; 5(6): 1-7. DOI: 10.4172/2329-6607.1000202.
15. Cuker A., Gimotty P.A., Crowther M.A., Warketin T.E. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012; 120: 4160-4167.
16. Rodeghiero F., Michel M., Gernsheimer T., Ruggeri M., Blanchette V., Bussel J.B., Cines D.B., Cooper N., Godeau B., Greinacher A., Imbach P., Khellaf M., Klaassen R.J., Kuhne T., Liebman H., Mazzucconi M.G., Newland A., Pabinger I., Tosetto A., Stasi R. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013; 121(14): 2596-2606.
17. Salter B., Weiner M., Trinh M., Heller J., Evans A., Adams D., Fischer G., Heparin-induced thrombocytopenia. A comprehensive clinical review. JACC. 2016; 67(21): 2519-2532.
18. Valgimigli M., Bueno H., Byrne R.A., Collet J-P., Costa F., Jeppsson A. Juni P., Kastrati A., Kolh P., Mauri L., Montalescot G., Neumann F-J., Petricevic M., Roffi M., Steg P.G., Windecker S., Zamorano J.L. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Authors/Task Force Members. European J CardioThoracic Surgery. 2018; 53(1): 34–78.
19. Lacy J., Bober-Sorcinelly K., Farber L., Glickman M. Acute thrombocytopenia induced by parenteral radiographic contrast medium. Am J Roentgenol. 1986; 146: 1298-1299.
20. Ferreira R., Filho J., Villela P., de Almeida J., Sampaio P., de Albuquerque F., Pulcheri W., Benchimol C., Contrast-induced thrombocytopenia following percutaneous coronary intervention. J Saudi Heart Assoc. 2017; 29: 227-229.
21. Bertrand M., Rupprecht H-J., Urban P., Gerschlick A. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000; 102: 624-629.
22. Bennett C., Connors J., Carwile J., Moake J., Bell W., Tarantolo S., McCarthy L., Sarode R., Hatfield A., Feldman M., Davidson C., Tsai H-M. Thrombotic thrombocytopenic purpura associated with clopidogrel. NEJM. 2000; 342: 17731777.
Review
For citations:
Sumarokov AB, Buryachkovskaya LI, Lomakin NV. Thrombocytopenia and prospective endovascular intervention in a patient with coronary artery disease. Meditsinskiy sovet = Medical Council. 2018;(21):16-21. (In Russ.) https://doi.org/10.21518/2079-701X-2018-21-16-21